ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 448,00
0,17%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Blueprint Medicines Corporation (BPMC)

  7. Blueprint Medicines Corporation (BPMC) Actualités

BPMC

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BPMC
DateHeureSourceTitreSymboleSociété
07/06/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
05/06/202423h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
31/05/202400h01PR Newswire (US)Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)NASDAQ:BPMCBlueprint Medicines Corporation
24/05/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPMCBlueprint Medicines Corporation
23/05/202423h05PR Newswire (US)Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
06/05/202422h01PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
02/05/202413h00PR Newswire (US)Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceNASDAQ:BPMCBlueprint Medicines Corporation
18/04/202414h00PR Newswire (US)Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024NASDAQ:BPMCBlueprint Medicines Corporation
11/04/202414h00PR Newswire (US)Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsNASDAQ:BPMCBlueprint Medicines Corporation
23/02/202414h00PR Newswire (US)Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
16/02/202422h40Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BPMCBlueprint Medicines Corporation
15/02/202423h26Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BPMCBlueprint Medicines Corporation
15/02/202413h00PR Newswire (US)Blueprint Medicines Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:BPMCBlueprint Medicines Corporation
01/02/202414h00PR Newswire (US)Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024NASDAQ:BPMCBlueprint Medicines Corporation
08/01/202414h00PR Newswire (US)Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
18/12/202314h00PR Newswire (US)Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
12/12/202314h05PR Newswire (US)Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
09/12/202318h30PR Newswire (US)Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
28/11/202314h00PR Newswire (US)Blueprint Medicines to Present at JMP Securities Hematology and Oncology SummitNASDAQ:BPMCBlueprint Medicines Corporation
10/11/202314h00PR Newswire (US)Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
26/10/202322h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BPMCBlueprint Medicines Corporation
26/10/202313h00PR Newswire (US)Blueprint Medicines Reports Third Quarter 2023 ResultsNASDAQ:BPMCBlueprint Medicines Corporation
23/10/202314h30PR Newswire (US)Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardNASDAQ:BPMCBlueprint Medicines Corporation
12/10/202314h00PR Newswire (US)Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023NASDAQ:BPMCBlueprint Medicines Corporation
02/08/202313h00PR Newswire (US)Blueprint Medicines Reports Second Quarter 2023 ResultsNASDAQ:BPMCBlueprint Medicines Corporation
19/07/202314h00PR Newswire (US)Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023NASDAQ:BPMCBlueprint Medicines Corporation
30/06/202312h08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BPMCBlueprint Medicines Corporation
24/06/202301h08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BPMCBlueprint Medicines Corporation
03/06/202315h00PR Newswire (US)Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
23/05/202316h00PR Newswire (US)NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
 Showing the most relevant articles for your search:NASDAQ:BPMC

Dernières Valeurs Consultées

EU
BNP
BNP Paribas
EU
DG
Vinci
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
EU
VK
Vallourec
EU
VIV
Vivendi
SPI
SP500
S&P 500
EU
BN
Danone
EU
MC
Lvmh Moet Hennessy Louis...
NASDAQ
AMZN
Amazon.com
NASDAQ
AAPL
Apple
EU
ORA
Orange
EU
AF
Air FranceKLM
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés